Comparative Efficacy and Safety of Baricitinib against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43927678" target="_blank" >RIV/00064173:_____/25:43927678 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/25:43927678
Result on the web
<a href="https://doi.org/10.1111/jocd.16666" target="_blank" >https://doi.org/10.1111/jocd.16666</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/jocd.16666" target="_blank" >10.1111/jocd.16666</a>
Alternative languages
Result language
angličtina
Original language name
Comparative Efficacy and Safety of Baricitinib against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
Original language description
Introduction: Alopecia areata is a common autoimmune disease which results in reversible hair loss. Janus kinase inhibitors are prescribed for severe alopecia areata with encouraging results. There are no studies comparing the efficacy and safety of Janus kinase inhibitors to traditional treatment options, such as topical immunomodulators and traditional immunosuppressants.AimsTo retrospectively compare the efficacy and safety of baricitinib, an approved Janus kinase inhibitor, to other treatments for severe AA during a 6-month treatment period. Materials/Methods: We included patients with newly presenting, relapsing or treatment-resistant alopecia areata with Severity of Alopecia Tool (SALT) score >= 50, for the period between July 2021 and July 2023. Medical histories were reviewed and possible side effects were recorded. Primary endpoints were SALT <= 20 and SALT <= 10 after 6 months of treatment. Results: Seventy-five patients (53 females) were divided into three groups: topical immunomodulators (51 patients); baricitinib (19 patients); and a group receiving pulsed intramuscular corticosteroids or traditional immunosuppressants (11 patients). Twenty-one patients received more than one treatment options within 2 years. After 6 months, the baricitinib group showed superior efficacy with 32% and 26% of patients achieving SALT <= 20 and SALT <= 10, compared to 12% and 9% in both other groups. Baricitinib demonstrated better secondary outcomes (50% and 90% reduction from initial SALT scores). All treatments exhibited mild-to-moderate and expected side effects. Weight gain, which had not been reported in clinical trials for alopecia areata, was observed in three baricitinib-treated patients. Conclusion: Baricitinib was superior to traditional treatments for severe alopecia areata after 6 months. Weight gain concerned 16% of patients receiving baricitinib.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Cosmetic Dermatology
ISSN
1473-2130
e-ISSN
1473-2165
Volume of the periodical
24
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
"e16666"
UT code for WoS article
001358893300001
EID of the result in the Scopus database
2-s2.0-85209805737